**Department of Health and Human Services**

**Part 1. Overview Information**

<table>
<thead>
<tr>
<th>Participating Organization(s)</th>
<th>National Institutes of Health (NIH)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Components of Participating Organizations</td>
<td>National Institute of Nursing Research (NINR)</td>
</tr>
<tr>
<td>Funding Opportunity Title</td>
<td>Health Promotion Among Racial and Ethnic Minority Males (R21)</td>
</tr>
<tr>
<td>Activity Code</td>
<td>R21 Exploratory/Developmental Research Grant</td>
</tr>
<tr>
<td>Announcement Type</td>
<td>Reissue of PA-10-237</td>
</tr>
<tr>
<td>Related Notices</td>
<td>- August 21, 2013: Removed reference to ASSIST in section IV.3, since ASSIST is currently only available for multi-project applications.</td>
</tr>
<tr>
<td>Funding Opportunity Announcement (FOA) Number</td>
<td>PA-13-331</td>
</tr>
<tr>
<td>Companion Funding Opportunity</td>
<td>PA-13-328, R01 Research Project Grant</td>
</tr>
<tr>
<td>Number of Applications</td>
<td>See Section III. 3. Additional Information on Eligibility.</td>
</tr>
<tr>
<td>Catalog of Federal Domestic Assistance (CFDA) Number(s)</td>
<td>93.361</td>
</tr>
<tr>
<td>Funding Opportunity Purpose</td>
<td>This initiative seeks applications from applicants that propose to stimulate and expand research in the health of minority men. Specifically, this initiative is intended to: 1) enhance our understanding of the numerous factors (e.g., sociodemographic, community, societal, personal) influencing the health promoting behaviors of racial and ethnic minority males and their subpopulations across the life cycle, and 2) encourage applications focusing on the development and testing of culturally and linguistically appropriate health-promoting interventions designed to reduce health disparities among racially and ethnically diverse males and their subpopulations age 21 and older.</td>
</tr>
</tbody>
</table>

**Key Dates**

| Posted Date | August 13, 2013 |
| Open Date (Earliest Submission Date) | September 16, 2013 |
| Letter of Intent Due Date(s) | Not Applicable |
| Application Due Date(s) | Standard dates, apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. |
Background

It is well documented that males experience approximately a five-year shorter life expectancy when compared with females. During the 20th century, life expectancy at birth increased from 48 to 74 years for males and from 51 to 79 years for females. Increases in life expectancy are, in part, attributed to improvements in lifestyle, nutrition, housing, hygiene and medical care. The disparities in life expectancy are more pronounced among men of color and economically disadvantaged males. For example, the life expectancy of European American males and African American males are 74.6 and 67.7 years respectively.

In 2005, the National Center for Health Statistics reported the leading causes of death in males as heart disease, cancer (lung and prostate), accidents, unintentional injuries, stroke, lung disease, diabetes, pneumonia, influenza, suicide, chronic liver
disease, and Alzheimers disease. Mortality rates from these causes of death are higher for minority males because their diseases are at a more advanced stage at diagnosis and are often complicated by co-existing conditions.

To illustrate, while cardiovascular disease is the leading cause of death for all Americans, white males have the greatest mortality from cardiovascular disease, 39.2% of all deaths, followed by 36.1% of all deaths for Asian American and Pacific Islander males, and 34.2% of all deaths for African American males. While Hispanic males experience the lowest death rate from cardiovascular disease, 27.9%, they suffer disproportionately from other conditions related to heart disease namely hypertension, high cholesterol and diabetes. African American males experience an earlier onset of the cardiovascular disease and experience a higher rate of complications. Cardiovascular disease mortality rates in African American males ages 35-64 are more than twice those of Caucasian males. One out of six African American men, ages 30-39, has hypertension, and by age 50-59, almost 60% are hypertensive. African American men also have low hypertension control rates and higher risk of fatality from stroke when compared to their White counterparts. In a recent analysis of the NHANES data, hypertension control rates were lower and the rates of severe hypertension (grade 2) were higher in Mexican Americans and Blacks (MMWR, May 10, 2013). The prevalence of obesity is higher among boys than girls (18.6% of boys and 15.0% of girls were obese). In 1999–2000, 27.5% of men were obese, and by 2009–2010 the prevalence had increased to 35.5%.

Other examples of health disparities noted among minority males include the following:

- The prevalence of extreme obesity in African American men is higher than in any other minority group. Among African American men, the prevalence of obesity increased from 27.5% in 1999-2000 to 31% in 2003-2004. Poor dietary patterns together with physical inactivity are highly prevalent in minority males and are major contributors to the high obesity prevalence rates.
- HIV infection is the third leading cause of death for Hispanic males ages 25-44, and the second leading cause of death in African American males within the same age group.
- Diabetes affects all racial and ethnic populations, but American Indians have the highest rate of diabetes in the world.

Insufficient sleep is a recognized public health problem that contributes to unintentional injuries and death (e.g., industrial disasters, medical and other occupational errors, motor vehicle crashes) and several chronic diseases including hypertension, diabetes, depression, cancer, and obesity. Racial disparities exist in sleep patterns.

Many of the disparities in health status noted among racial and ethnically diverse male populations are related to lifestyle and are either preventable or amenable to early detection or intervention. For example, tobacco use constitutes the single most preventable cause of premature death in the US. In 2004, an estimated 44.5 million adults in the United States were smokers - 23.4% of men and 18.5% of women. Cigarette smoking was highest among male Alaska Natives (33.4%), followed by African Americans (23.9%), Hispanics (18.9%), and Asian/Pacific Islanders (17.8%).

Similarly, many unintentional injuries are preventable and can be prevented if intervention is instituted early. According to epidemiologists, Over 400 Americans die each day from unintentional injuries such as motor vehicle crashes, poisonings, drowning, falls, fires, suffocation, and firearms. A major objective outlined by Healthy People 2010 is to reduce deaths from unintentional injuries from baseline 35.0 deaths per 100,000 populations to 17.5 deaths per 100,000 populations.

Males are more likely than females to experience death from unintentional injury. Minority males are more at risk to die from such injuries when compared with their White counterparts. For example, in 2004 the death rate for unintentional injuries is 51.6 per 1000,000 deaths (year) for white males. The death rate for unintentional injuries is 51.6 per 100,000 deaths for White males. This compares with 72.5 deaths per 100,000 for American Indian/Alaska Native males followed by 55.6 per 100,000 deaths for African American males and 44.7 per 100,000 deaths for Hispanic males. The disparities in health are often more pronounced among underserved and uninsured racial and ethnic minority males who often delay in seeking clinical care. There are ample data highlighting that uninsured individuals experience greater declines in health status and die prematurely from a variety of illnesses when compared to those with continuous health care coverage. This is particularly important given that racial and ethnic minority populations are disproportionately represented among the uninsured. For example, in 2005, 23% of African American males were uninsured followed by 30.7% of Hispanic males. This compares with 11.2% White males. These and other health disparities noted among minority males require greater elucidation and intervention.

**Scope of Research**

The National Institutes of Health (NIH) Exploratory/Developmental Grant (R21) funding opportunity supports the development of new research activities in categorical program areas. The R21 mechanism is intended to encourage exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. The focus of this FOA is on health promotion among racial and ethnic minority men. A scientific exploration of these disparities is central to NIH's commitment to reducing health disparities. Research in this area is essential to addressing Goal 2 outlined in Healthy People.
2010: "To eliminate health disparities among segments of the population, including differences that occur by gender, race or ethnicity, education or income, disability, geographic location or sexual orientation." Generally men access primary care facilities less often than women and are thus more inclined to delay accessing diagnostic services and treatments. Thus interventions in this area of study need to be innovative and cognizant of these patterns.

The following are potential areas of research related to this announcement. These suggested areas of research are not listed in any priority and are not to be viewed as an exhaustive or exclusive list. Investigators responding to this announcement may target other groups of minority males (e.g., men of diverse sexual orientation, migrant workers, disabled men, rural and immigrant men).

Potential research topics include but are not limited to:

- Studies that test innovative interventions to reduce risk factors associated with the leading causes of morbidity and mortality (e.g., smoking, poor nutrition, alcohol use, sedentary lifestyle, risky sexual behavior) among racial and ethnic minority men and their subpopulations in rural, urban, and nontraditional settings, including interventions addressing multiple risk factors in the same individual.
- Multifaceted interventions designed to increase both initial and repeat health screenings and risk assessment among racial and ethnic minority and underserved men.
- Research to understand and promote informed decision making among minority males about the PSA test to screen for prostate cancer. Questions may include: How do attitudes towards informed decision making in health care influence men’s use of the PSA test? What factors (interpersonal, community, individual) influence men in their decisions to have the PSA test to screen for prostate cancer?
- Studies that include innovative approaches involving families, social networks, or communities in interventions designed to enhance health-promotion structures and behaviors.
- Unique interventions developed to promote positive physical and mental health seeking, health maintenance, and symptom management behaviors among diverse groups of men examining pathways between childhood and adult health.
- Obesity prevention and treatment interventions that target Hispanic and African American boys, and/or Hispanic and African American men.
- Innovative interventions that target African American boys and/or men for blood pressure screening, identification, prevention and treatment.
- Interventions that incorporate faith, cultural and family values and are designed to test the effects of unique and creative intergenerational health promotion activities.
- Interventions that target two or more high-risk behaviors in a single application, e.g., tobacco use, risky sexual behaviors, unintentional (accidents) and intentional behaviors (firearm related injuries.)
- Culturally and linguistically appropriate studies designed to enhance self-efficacy, competence, and skill development to support the initiation and maintenance of health promoting behaviors.
- Studies that develop and test strategies to increase the use of best practices in men's health, such as evidence based guidelines or research syntheses, in health care settings.
- Studies that include innovative biopsychosocial and biobehavioral approaches.
- Studies that include innovative applications of mobile health and other technologies in interventions designed to enhance health-promotion behaviors and/or to reduce health risk behaviors.

### Section II. Award Information

<table>
<thead>
<tr>
<th>Funding Instrument</th>
<th>Grant: A support mechanism providing money, property, or both to an eligible entity to carry out an approved project or activity.</th>
</tr>
</thead>
</table>
| Application Types Allowed | New  
Resubmission  
The [OER Glossary](#) and the SF424 (R&R) Application Guide provide details on these application types. |
| Funds Available and Anticipated Number of Awards | The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. |
| Award Budget | The combined budget for direct costs for the two (2) year project period may not |
exceed $275,000. No more than $200,000 in direct costs may be requested in any single year.

| Award Project Period | The maximum project period is two (2) years. |

NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made in response to this FOA.

Section III. Eligibility Information

1. Eligible Applicants

Eligible Organizations

Higher Education Institutions

- Public/State Controlled Institutions of Higher Education
- Private Institutions of Higher Education

The following types of Higher Education Institutions are always encouraged to apply for NIH support as Public or Private Institutions of Higher Education:

- Hispanic-serving Institutions
- Historically Black Colleges and Universities (HBCUs)
- Tribally Controlled Colleges and Universities (TCCUs)
- Alaska Native and Native Hawaiian Serving Institutions
- Asian American Native American Pacific Islander Serving Institutions (AANAPIISIs)

Nonprofits Other Than Institutions of Higher Education

- Nonprofits with 501(c)(3) IRS Status (Other than Institutions of Higher Education)
- Nonprofits without 501(c)(3) IRS Status (Other than Institutions of Higher Education)

For-Profit Organizations

- Small Businesses
- For-Profit Organizations (Other than Small Businesses)

Governments

- State Governments
- County Governments
- City or Township Governments
- Special District Governments
- Indian/Native American Tribal Governments (Federally Recognized)
- Indian/Native American Tribal Governments (Other than Federally Recognized)
- Eligible Agencies of the Federal Government
- U.S. Territory or Possession

Other

- Independent School Districts
- Public Housing Authorities/Indian Housing Authorities
- Native American Tribal Organizations (other than Federally recognized tribal governments)
- Faith-based or Community-based Organizations
- Regional Organizations
- Non-domestic (non-U.S.) Entities (Foreign Institutions)

Foreign Institutions
Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.

Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

**Required Registrations**

**Applicant Organizations**

Applicant organizations must complete and maintain the following registrations as described in the SF 424 (R&R) Application Guide to be eligible to apply for or receive an award. All registrations must be completed prior to the application being submitted. Registration can take 6 weeks or more, so applicants should begin the registration process as soon as possible. The NIH Policy on Late Submission of Grant Applications states that failure to complete registrations in advance of a due date is not a valid reason for a late submission.

- **Dun and Bradstreet Universal Numbering System (DUNS)** - All registrations require that applicants be issued a DUNS number. After obtaining a DUNS number, applicants can begin both SAM and eRA Commons registrations. The same DUNS number must be used for all registrations, as well as on the grant application.
- **System for Award Management (SAM)** (formerly CCR) – Applicants must complete and maintain an active registration, which requires renewal at least annually. The renewal process may require as much time as the initial registration. SAM registration includes the assignment of a Commercial and Government Entity (CAGE) Code for domestic organizations which have not already been assigned a CAGE Code.
- **NATO Commercial and Government Entity (NCAGE) Code** – Foreign organizations must obtain an NCAGE code (in lieu of a CAGE code) in order to register in SAM.
- **eRA Commons** - Applicants must have an active DUNS number and SAM registration in order to complete the eRA Commons registration. Organizations can register with the eRA Commons as they are working through their SAM or Grants.gov registration. eRA Commons requires organizations to identify at least one Signing Official (SO) and at least one Program Director/Principal Investigator (PD/PI) account in order to submit an application.
- **Grants.gov** – Applicants must have an active DUNS number and SAM registration in order to complete the Grants.gov registration.

**Program Directors/Principal Investigators (PD(s)/PI(s))**

All PD(s)/PI(s) must have an eRA Commons account and should work with their organizational officials to either create a new account or to affiliate an existing account with the applicant organization’s eRA Commons account. If the PD/PI is also the organizational Signing Official, they must have two distinct eRA Commons accounts, one for each role. Obtaining an eRA Commons account can take up to 2 weeks.

**Eligible Individuals (Program Director/Principal Investigator)**

Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.

For institutions/organizations proposing multiple PDs/PIs, visit the Multiple Program Director/Principal Investigator Policy and submission details in the Senior/Key Person Profile (Expanded) Component of the SF424 (R&R) Application Guide.

**2. Cost Sharing**

This FOA does not require cost sharing as defined in the NIH Grants Policy Statement.

**3. Additional Information on Eligibility**

**Number of Applications**

Applicant organizations may submit more than one application, provided that each application is scientifically distinct.

NIH will not accept any application that is essentially the same as one already reviewed within the past thirty-seven months (as described in the NIH Grants Policy Statement), except for submission.
To an RFA of an application that was submitted previously as an investigator-initiated application but not paid;
Of an investigator-initiated application that was originally submitted to an RFA but not paid; or
Of an application with a changed grant activity code.

Section IV. Application and Submission Information

1. Requesting an Application Package

Applicants must download the SF424 (R&R) application package associated with this funding opportunity using the “Apply for Grant Electronically” button in this FOA or following the directions provided at Grants.gov.

2. Content and Form of Application Submission

It is critical that applicants follow the instructions in the SF424 (R&R) Application Guide, except where instructed in this funding opportunity announcement to do otherwise. Conformance to the requirements in the Application Guide is required and strictly enforced. Applications that are out of compliance with these instructions may be delayed or not accepted for review.

For information on Application Submission and Receipt, visit Frequently Asked Questions – Application Guide, Electronic Submission of Grant Applications.

Page Limitations

All page limitations described in the SF424 Application Guide and the Table of Page Limits must be followed.

Required and Optional Components

The forms package associated with this FOA includes all applicable components, required and optional. Please note that some components marked optional in the application package are required for submission of applications for this FOA. Follow all instructions in the SF424 (R&R) Application Guide to ensure you complete all appropriate “optional” components.

Instructions for Application Submission

The following section supplements the instructions found in the SF424 (R&R) Application Guide and should be used for preparing an application to this FOA.

SF424(R&R) Cover

All instructions in the SF424 (R&R) Application Guide must be followed.

SF424(R&R) Project/Performance Site Locations

All instructions in the SF424 (R&R) Application Guide must be followed.

SF424(R&R) Other Project Information

All instructions in the SF424 (R&R) Application Guide must be followed.

SF424(R&R) Senior/Key Person Profile

All instructions in the SF424 (R&R) Application Guide must be followed.

R&R or Modular Budget

All instructions in the SF424 (R&R) Application Guide must be followed.

PHS 398 Cover Page Supplement

All instructions in the SF424 (R&R) Application Guide must be followed.

PHS 398 Research Plan

All instructions in the SF424 (R&R) Application Guide must be followed, with the following additional instructions:
**Resource Sharing Plan**: Individuals are required to comply with the instructions for the Resource Sharing Plans (Data Sharing Plan, Sharing Model Organisms, and Genome Wide Association Studies (GWAS)) as provided in the SF424 (R&R) Application Guide, with the following modification:

- All applications, regardless of the amount of direct costs requested for any one year, should address a Data Sharing Plan.

**Appendix**: Do not use the Appendix to circumvent page limits. Follow all instructions for the Appendix as described in the SF424 (R&R) Application Guide.

**Planned Enrollment Report**

When conducting clinical research, follow all instructions for completing Planned Enrollment Reports as described in the SF424 (R&R) Application Guide.

**PHS 398 Cumulative Inclusion Enrollment Report**

When conducting clinical research, follow all instructions for completing Cumulative Inclusion Enrollment Report as described in the SF424 (R&R) Application Guide.

**Foreign Institutions**

Foreign (non-U.S.) institutions must follow policies described in the [NIH Grants Policy Statement](#), and procedures for foreign institutions described throughout the SF424 (R&R) Application Guide.

### 3. Submission Dates and Times

[Part I. Overview Information](#) contains information about Key Dates. Applicants are encouraged to submit applications before the due date to ensure they have time to make any application corrections that might be necessary for successful submission.

Organizations must submit applications to [Grants.gov](#), the online portal to find and apply for grants across all Federal agencies. Applicants must then complete the submission process by tracking the status of the application in the [eRA Commons](#), NIH’s electronic system for grants administration. NIH and Grants.gov systems check the application against many of the application instructions upon submission. Errors must be corrected and a changed/corrected application must be submitted to Grants.gov on or before the application due date. If a Changed/Corrected application is submitted after the deadline, the application will be considered late.

Applicants are responsible for viewing their application before the due date in the eRA Commons to ensure accurate and successful submission.

Information on the submission process and a definition of on-time submission are provided in the SF424 (R&R) Application Guide.

### 4. Intergovernmental Review (E.O. 12372)

This initiative is not subject to [intergovernmental review](#).

### 5. Funding Restrictions

All NIH awards are subject to the terms and conditions, cost principles, and other considerations described in the [NIH Grants Policy Statement](#).

Pre-award costs are allowable only as described in the [NIH Grants Policy Statement](#).

### 6. Other Submission Requirements and Information

Applications must be submitted electronically following the instructions described in the SF424 (R&R) Application Guide. Paper applications will not be accepted.

Applicants must complete all required registrations before the application due date. [Section III. Eligibility Information](#) contains information about registration.

For assistance with your electronic application or for more information on the electronic submission process, visit [Applying](#).
Important reminders:
All PD(s)/PI(s) must include their eRA Commons ID in the Credential field of the Senior/Key Person Profile Component of the SF424(R&R) Application Package. Failure to register in the Commons and to include a valid PD/PI Commons ID in the credential field will prevent the successful submission of an electronic application to NIH. See Section III of this FOA for information on registration requirements.

The applicant organization must ensure that the DUNS number it provides on the application is the same number used in the organization’s profile in the eRA Commons and for the System for Award Management. Additional information may be found in the SF424 (R&R) Application Guide.

See more tips for avoiding common errors.

Upon receipt, applications will be evaluated for completeness by the Center for Scientific Review, NIH. Applications that are incomplete will not be reviewed.

Post-Submission Materials
Applicants are required to follow the instructions for post-submission materials, as described in NOT-OD-13-030.

Section V. Application Review Information

1. Criteria

Only the review criteria described below will be considered in the review process. As part of the NIH mission, all applications submitted to the NIH in support of biomedical and behavioral research are evaluated for scientific and technical merit through the NIH peer review system.

For this particular announcement, note the following:

The R21 exploratory/developmental grant supports investigation of novel scientific ideas or new model systems, tools, or technologies that have the potential for significant impact on biomedical or biobehavioral research. An R21 grant application need not have extensive background material or preliminary information. Accordingly, reviewers will focus their evaluation on the conceptual framework, the level of innovation, and the potential to significantly advance our knowledge or understanding. Appropriate justification for the proposed work can be provided through literature citations, data from other sources, or, when available, from investigator-generated data. Preliminary data are not required for R21 applications; however, they may be included if available.

Overall Impact

Reviewers will provide an overall impact score to reflect their assessment of the likelihood for the project to exert a sustained, powerful influence on the research field(s) involved, in consideration of the following review criteria and additional review criteria (as applicable for the project proposed).

Scored Review Criteria

Reviewers will consider each of the review criteria below in the determination of scientific merit, and give a separate score for each. An application does not need to be strong in all categories to be judged likely to have major scientific impact. For example, a project that by its nature is not innovative may be essential to advance a field.

Significance

Does the project address an important problem or a critical barrier to progress in the field? If the aims of the project are achieved, how will scientific knowledge, technical capability, and/or clinical practice be improved? How will successful completion of the aims change the concepts, methods, technologies, treatments, services, or preventative interventions that drive this field?

Investigator(s)
Are the PD(s)/PI(s), collaborators, and other researchers well suited to the project? If Early Stage Investigators or New Investigators, or in the early stages of independent careers, do they have appropriate experience and training? If established, have they demonstrated an ongoing record of accomplishments that have advanced their field(s)? If the project is collaborative or multi-PD/PI, do the investigators have complementary and integrated expertise; are their leadership approach, governance and organizational structure appropriate for the project?

**Innovation**

Does the application challenge and seek to shift current research or clinical practice paradigms by utilizing novel theoretical concepts, approaches or methodologies, instrumentation, or interventions? Are the concepts, approaches or methodologies, instrumentation, or interventions novel to one field of research or novel in a broad sense? Is a refinement, improvement, or new application of theoretical concepts, approaches or methodologies, instrumentation, or interventions proposed?

**Approach**

Are the overall strategy, methodology, and analyses well-reasoned and appropriate to accomplish the specific aims of the project? Are potential problems, alternative strategies, and benchmarks for success presented? If the project is in the early stages of development, will the strategy establish feasibility and will particularly risky aspects be managed?

If the project involves clinical research, are the plans for 1) protection of human subjects from research risks, and 2) inclusion of minorities and members of both sexes/genders, as well as the inclusion of children, justified in terms of the scientific goals and research strategy proposed?

**Environment**

Will the scientific environment in which the work will be done contribute to the probability of success? Are the institutional support, equipment and other physical resources available to the investigators adequate for the project proposed? Will the project benefit from unique features of the scientific environment, subject populations, or collaborative arrangements?

**Additional Review Criteria**

As applicable for the project proposed, reviewers will evaluate the following additional items while determining scientific and technical merit, and in providing an overall impact score, but will not give separate scores for these items.

**Protections for Human Subjects**

For research that involves human subjects but does not involve one of the six categories of research that are exempt under 45 CFR Part 46, the committee will evaluate the justification for involvement of human subjects and the proposed protections from research risk relating to their participation according to the following five review criteria: 1) risk to subjects, 2) adequacy of protection against risks, 3) potential benefits to the subjects and others, 4) importance of the knowledge to be gained, and 5) data and safety monitoring for clinical trials.

For research that involves human subjects and meets the criteria for one or more of the six categories of research that are exempt under 45 CFR Part 46, the committee will evaluate: 1) the justification for the exemption, 2) human subjects involvement and characteristics, and 3) sources of materials. For additional information on review of the Human Subjects section, please refer to the Guidelines for the Review of Human Subjects.

**Inclusion of Women, Minorities, and Children**

When the proposed project involves clinical research, the committee will evaluate the proposed plans for inclusion of minorities and members of both genders, as well as the inclusion of children. For additional information on review of the Inclusion section, please refer to the Guidelines for the Review of Inclusion in Clinical Research.

**Vertebrate Animals**

The committee will evaluate the involvement of live vertebrate animals as part of the scientific assessment according to the following five points: 1) proposed use of the animals, and species, strains, ages, sex, and numbers to be used; 2) justifications for the use of animals and for the appropriateness of the species and numbers proposed; 3) adequacy of veterinary care; 4) procedures for limiting discomfort, distress, pain and injury to that which is unavoidable in the conduct of
scientifically sound research including the use of analgesic, anesthetic, and tranquilizing drugs and/or comfortable restraining devices; and 5) methods of euthanasia and reason for selection if not consistent with the AVMA Guidelines on Euthanasia. For additional information on review of the Vertebrate Animals section, please refer to the Worksheet for Review of the Vertebrate Animal Section.

Biohazards

Reviewers will assess whether materials or procedures proposed are potentially hazardous to research personnel and/or the environment, and if needed, determine whether adequate protection is proposed.

Resubmissions

For Resubmissions, the committee will evaluate the application as now presented, taking into consideration the responses to comments from the previous scientific review group and changes made to the project.

Renewals

Not Applicable

Revisions

Not Applicable

Additional Review Considerations

As applicable for the project proposed, reviewers will consider each of the following items, but will not give scores for these items, and should not consider them in providing an overall impact score.

Applications from Foreign Organizations

Reviewers will assess whether the project presents special opportunities for furthering research programs through the use of unusual talent, resources, populations, or environmental conditions that exist in other countries and either are not readily available in the United States or augment existing U.S. resources.

Select Agent Research

Reviewers will assess the information provided in this section of the application, including 1) the Select Agent(s) to be used in the proposed research, 2) the registration status of all entities where Select Agent(s) will be used, 3) the procedures that will be used to monitor possession use and transfer of Select Agent(s), and 4) plans for appropriate biosafety, biocontainment, and security of the Select Agent(s).

Resource Sharing Plans

Reviewers will comment on whether the following Resource Sharing Plans, or the rationale for not sharing the following types of resources, are reasonable: 1) Data Sharing Plan; 2) Sharing Model Organisms; and 3) Genome Wide Association Studies (GWAS).

Budget and Period of Support

Reviewers will consider whether the budget and the requested period of support are fully justified and reasonable in relation to the proposed research.

2. Review and Selection Process

Applications will be evaluated for scientific and technical merit by (an) appropriate Scientific Review Group(s), in accordance with NIH peer review policy and procedures, using the stated review criteria. Assignment to a Scientific Review Group will be shown in the eRA Commons.

As part of the scientific peer review, all applications:

- May undergo a selection process in which only those applications deemed to have the highest scientific and technical
merit (generally the top half of applications under review) will be discussed and assigned an overall impact score.
  - Will receive a written critique.

Applications will be assigned on the basis of established PHS referral guidelines to the appropriate NIH Institute or Center. Applications will compete for available funds with all other recommended applications. Following initial peer review, recommended applications will receive a second level of review by the appropriate national Advisory Council or Board. The following will be considered in making funding decisions:
  - Scientific and technical merit of the proposed project as determined by scientific peer review.
  - Availability of funds.
  - Relevance of the proposed project to program priorities.

3. Anticipated Announcement and Award Dates

After the peer review of the application is completed, the PD/PI will be able to access his or her Summary Statement (written critique) via the eRA Commons.

Information regarding the disposition of applications is available in the NIH Grants Policy Statement.

Section VI. Award Administration Information

1. Award Notices

If the application is under consideration for funding, NIH will request “just-in-time” information from the applicant as described in the NIH Grants Policy Statement.

A formal notification in the form of a Notice of Award (NoA) will be provided to the applicant organization for successful applications. The NoA signed by the grants management officer is the authorizing document and will be sent via email to the grantee’s business official.

Awardees must comply with any funding restrictions described in Section IV.5. Funding Restrictions. Selection of an application for award is not an authorization to begin performance. Any costs incurred before receipt of the NoA are at the recipient's risk. These costs may be reimbursed only to the extent considered allowable pre-award costs.

Any application awarded in response to this FOA will be subject to the DUNS, SAM Registration, and Transparency Act requirements as noted on the Award Conditions and Information for NIH Grants website.

2. Administrative and National Policy Requirements

All NIH grant and cooperative agreement awards include the NIH Grants Policy Statement as part of the NoA. For these terms of award, see the NIH Grants Policy Statement Part II: Terms and Conditions of NIH Grant Awards, Subpart A: General and Part II: Terms and Conditions of NIH Grant Awards, Subpart B: Terms and Conditions for Specific Types of Grants, Grantees, and Activities. More information is provided at Award Conditions and Information for NIH Grants.

Cooperative Agreement Terms and Conditions of Award

Not Applicable

3. Reporting

When multiple years are involved, awardees will be required to submit the annual Non-Competing Progress Report (PHS 2590 or RPPR) and financial statements as required in the NIH Grants Policy Statement.

A final progress report, invention statement, and the expenditure data portion of the Federal Financial Report are required for closeout of an award, as described in the NIH Grants Policy Statement.

issued in FY2011 or later. All awardees of applicable NIH grants and cooperative agreements are required to report to the Federal Subaward Reporting System (FSRS) available at www.fsrs.gov on all subawards over $25,000. See the NIH Grants Policy Statement for additional information on this reporting requirement.

Section VII. Agency Contacts

We encourage inquiries concerning this funding opportunity and welcome the opportunity to answer questions from potential applicants.

Application Submission Contacts

eRA Commons Help Desk (Questions regarding eRA Commons registration, submitting and tracking an application, documenting system problems that threaten submission by the due date, post submission issues)
Telephone: 301-402-7469 or 866-504-9552 (Toll Free)

Web ticketing system: https://public.era.nih.gov/commonshelp
TTY: 301-451-5939
Email: commons@od.nih.gov

Grants.gov Customer Support (Questions regarding Grants.gov registration and submission, downloading forms and application packages)
Contact Center Telephone: 800-518-4726

Web ticketing system: https://grants-portal.psc.gov/ContactUs.aspx
Email: support@grants.gov

GrantsInfo (Questions regarding application instructions and process, finding NIH grant resources)
Telephone: 301-435-0714
TTY: 301-451-5936
Email: GrantsInfo@nih.gov

Scientific/Research Contact(s)

Paul A. Cotton, PhD, RD
National Institute of Nursing Research
Telephone: 301-402-6423
Email: cottonp@mail.nih.gov

Peer Review Contact(s)

Examine your eRA Commons account for review assignment and contact information (information appears two weeks after the submission due date).

Financial/Grants Management Contact(s)

Judy Lee Sint
National Institute of Nursing Research
Telephone: 301-402-6959
Email: sintj@mail.nih.gov

Section VIII. Other Information

Recently issued trans-NIH policy notices may affect your application submission. A full list of policy notices published by NIH is provided in the NIH Guide for Grants and Contracts. All awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.

Authority and Regulations

file:///C|/Users/kthomas/Documents/Grant%20Announcements/11.28.12/PA-13-331.html[8/29/2013 3:18:00 PM]
Awards are made under the authorization of Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 45 CFR Parts 74 and 92.

Weekly TOC for this Announcement
NIH Funding Opportunities and Notices

Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.